Our Services
Medical Information
Helpful Resources
Published on: 5/6/2026
Bremelanotide commonly causes mild nausea, headache, flushing, and injection-site reactions as your body adapts to melanocortin receptor activation and vasodilation. These effects typically resolve within a few hours and can be managed with hydration, over-the-counter pain relievers, and rotating injection sites.
Rarer but serious effects—such as significant blood pressure changes or prolonged skin darkening—warrant closer monitoring and prompt medical attention. Because side effects can overlap with other conditions and vary widely between individuals, it's important to clarify what you're experiencing before deciding on next steps.
A free, instant, online symptom check can help you evaluate your symptoms in minutes, identify possible causes, and guide you toward the right care—so you can move forward with clarity and confidence.
Reviewed for medical accuracy: 06/24/2026
Bremelanotide Side Effects? Why Your Body Reacts & Medical Next Steps
Bremelanotide (brand name Vyleesi) is an injectable medication approved by the FDA to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Like all drugs, it can cause side effects. Understanding what's common, why these reactions occur, and how to manage them helps you get the benefits of Bremelanotide safely.
Most people tolerate Bremelanotide well. The most frequently reported side effects are:
These side effects tend to be mild to moderate and diminish as your body adjusts over the first few doses.
Bremelanotide works by activating melanocortin receptors in the brain, which play a role in sexual response pathways. Here's how this leads to side effects:
Melanocortin Receptor Activation
Vasodilation
CNS Effects
Peripheral Effects
Understanding these mechanisms can help you anticipate and manage side effects rather than be alarmed by them.
While most reactions are mild, a small percentage of users may experience more serious effects:
If you have a history of cardiovascular disease, migraine with aura, or severe nodule/mole changes, discuss risks with your doctor before starting Bremelanotide.
Many side effects can be managed at home or with simple measures:
Keep a simple side-effect diary noting timing, severity, and duration. This helps your doctor fine-tune dosing and supportive measures.
Contact a healthcare professional immediately if you experience:
Even if you're unsure whether your symptoms require immediate attention, you can use Ubie's free AI symptom checker to quickly assess your symptoms and get guidance on the appropriate next steps for your situation.
Bremelanotide can be a game-changer for women with HSDD, but proper medical oversight ensures safety:
Never adjust your dose or frequency without consulting your healthcare provider.
Final Thoughts
Bremelanotide's most common side effects—nausea, headache, flushing, and injection-site reactions—are usually mild and manageable. They stem from its mechanism as a melanocortin receptor agonist affecting both central and peripheral pathways. Serious reactions are uncommon but warrant prompt medical attention.
If you're experiencing side effects and need help deciding whether to contact your doctor, try Ubie's AI-powered symptom checker for personalized guidance based on your specific symptoms. And remember: for anything life-threatening or serious, speak to a doctor right away. Your physician can tailor strategies to minimize side effects and optimize your treatment outcome.
(References)
* Kingsberg SA, et al. Bremelanotide for Hypoactive Sexual Desire Disorder: A Review of Efficacy and Safety. J Womens Health (Larchmt). 2021 Mar;30(3):308-316. doi: 10.1089/jwh.2020.8875. Epub 2021 Jan 19. PMID: 33467652.
* Clayton AH, et al. Safety and tolerability of bremelanotide in women with hypoactive sexual desire disorder: an open-label, long-term study. Menopause. 2021 Apr 1;28(4):427-434. doi: 10.1097/GME.0000000000001718. PMID: 33507119.
* DeRogatis LR, et al. Pharmacologic Management of Hypoactive Sexual Desire Disorder in Women: An Update. Sex Med Rev. 2022 Jan;10(1):154-173. doi: 10.1016/j.sxmr.2021.05.002. Epub 2021 Jun 1. PMID: 34103328.
* Krysiak R, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder. Pharmacol Rep. 2020 Feb;72(1):1-10. doi: 10.1007/s43440-019-00002-1. Epub 2020 Jan 8. PMID: 31916323.
* Palace-Bramel E, et al. Mechanism of Action and Clinical Profile of Bremelanotide: A Melanocortin Receptor Agonist for Hypoactive Sexual Desire Disorder. J Sex Med. 2020 Jan;17(1):11-20. doi: 10.1016/j.jsxm.2019.09.006. Epub 2019 Oct 29. PMID: 31676239.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.